A PK/PD Study of Polyethylene Glycol Loxenatide in Patients With Type 2 Diabetes

NCT01965509 · Completed

Last updated 2026-05-28

This study tests how a medication called polyethylene glycol loxenatide affects blood sugar levels in adults with type 2 diabetes.

Status Completed The study has finished.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, quadruple-blind treatment study

Participants 120 people

Who can join Ages 20–70 · all sexes

Timeline Started 2012-05 · est. completion 2013-10

Where 1 site · China

What this study is testing ClinicalTrials.gov NCT01965509 ↗

Description as written by the study sponsor.

Polyethylene Glycol Loxenatide (PEX168) is a new human glucagon-like peptide 1 (GLP-1) analogue that created on the basis of the Exenatide and modified by polyethylene glycol (PEG). This study aims to evaluate the effective therapeutic concentration range of PEX168, also decided to observe safety and PK/PD correlation by long-term continuous administration.

Treatments tested

PEX168 or placebo also known as Polyethylene Glycol Loxenatide or Placebo Drug

injection has to administered subcutaneously weekly

Main thing measured	To assess HbA1C levels after treatment
Sponsor	Jiangsu HengRui Medicine Co., Ltd.
Conditions studied	Type 2 Diabetes
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT01965509 ↗